News
Foot exercise device designed to treat symptoms of arthritis

A foot strengthening and mobility device which may help people with arthritis of the joints in their feet will be launched onto the market this summer.
Gerry Farrell, a dentist from Glasgow, created the Novabow device with specialist designers and advisers from the Medical Device Manufacturing Centre at Heriot-Watt University.
“My patented foot exercise device has evolved into a powerful tool for clinicians to help treat a whole range of painful foot conditions which may respond to conservative treatments like muscle strengthening and improvement of foot joint mobility,” he told Age Tech World.
“Arthritis is a condition which commonly affects the foot with the big toe joint being an area that can be particularly affected.
“This condition can have a big impact on everyday activities like walking or taking part in sports.”
Strengthening
Flexibility and range of motion exercises are the most commonly recommended treatment for arthritis in the big toe followed by intrinsic and extrinsic muscle strengthening exercises, a 2020 study found.
“The Novabow foot exercise system makes these types of exercises easy to complete,” Farrell said, “when this might otherwise be difficult especially for older, less mobile, patients who have difficulty reaching their feet.”
While there is some consensus about conservative treatment of arthritis of the big toe joint, much less is known about treating arthritis affecting the mid-foot, largely due to a lack of research in the area.
However, some evidence concerning this common and debilitating condition is now starting to emerge.
UK research in 2020 said: “People with symptomatic midfoot OA (osteoarthritis) demonstrate weakness in the foot and leg muscles compared to asymptomatic controls.
“Preliminary indications from this study suggest that strengthening of the foot and leg muscles may offer potential to reduce pain and improve function in people with midfoot OA.”
Weakness
A recent study has demonstrated that modern footwear makes intrinsic foot muscles weak, with six months of using more minimal shoes improving toe flexor strength by a huge 57 per cent in the study group.
Intrinsic foot muscle weakness is believed to contribute towards lesser toe deformity and to the development of bunions which may then develop painful arthritic complications.
“The Novabow System offers an alternative to weak feet,” Farrell, who founded the company Jomarg Innovation to produce his product, said.
“I am confident it will become a standard tool for physicians dealing with a whole range of conditions affecting the foot, both as a conservative treatment for existing conditions and as a tool for helping to prevent these conditions from developing in the first place.”
Potential
Professor Marc Desmulliez, manager of the Medical Device Manufacturing Centre (MDMC) at Heriot-Watt University, said he can see enormous potential for the Novabow device.
He said it may address and prevent a wide range of health conditions as well as support both amateur and professional sportspeople to exercise safety.
“The MDMC has been established to help SMEs like Jomarg Innovation to source the right manufacturers for their product, to fully utilise our £2 million lab equipment with expert guidance and to navigate the challenging path of medical device regulation.
“Our support is free to Scottish SMEs, demonstrating our institution’s commitment to accelerating life sciences innovation in Scotland and beyond.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








